TABLE 1.
Sample demographics and baseline characteristics by condition
| THC | THC ± CBD | CBD | |
|---|---|---|---|
| n = 57 | n = 51 | n = 51 | |
| Demographics | |||
| Age | 36.19 (15.27) | 35.80 (16.47) | 36.19 (15.95) |
| Gender (% female) | 38.60% | 43.14% | 41.18% |
| Marital status (% married) | 17.54% | 25.49% | 29.42% |
| Education (% BACHELORS OR HIGHER) | 47.37% | 45.10% | 58.82% |
| Employment (% full-time employed) | 49.12% | 31.37% | 49.02% |
| Race (% non-Hispanic White) | 82.46% | 76.47% | 84.31% |
| Body mass index (BMI) | 23.08 (3.38) | 25.03 (5.13) | 23.89 (5.20) |
| Cannabis history and current use | |||
| Age of onset of regular cannabis use | 19.86 (9.05) | 21.96 (10.42) | 20.28 (7.19) |
| Cannabis use disorder score | 2.56 (2.34) | 2.18 (2.64) | 2.65 (2.54) |
| Days of flower usea (past 30 days) | 18.18 (11.22) | 17.61 (10.98) | 17.39 (11.58) |
| Days of concentrate usea (past 30 days) | 5.53 (9.06) | 4.37 (8.17) | 6.25 (9.60) |
| Days of edible usea (past 30 days) | 3.46 (7.89) | 1.39 (5.48) | 2.90 (7.20) |
| Baseline plasma THC (ng/ml) | 4.90 (6.18) | 7.08 (15.09) | 4.13 (6.19) |
| Baseline plasma CBD (ng/ml) | .65 (1.61) | .53 (1.73) | .51 (2.06) |
| Baseline plasma THCV (ng/ml) | .00 (.00) | .06 (.27) | .00 (.00) |
| Baseline plasma CBN (ng/ml) | .00 (.00) | .12 (.59) | .02 (.16) |
| Baseline plasma CBG (ng/ml) | .02 (.11) | .10 (.48) | .00 (.00) |
| Baseline plasma CBC (ng/ml) | .21 (.51) | .36 (1.30) | .10 (.34) |
| Other substance use factors | |||
| Days of alcohol usea (past 30 days) | 8.25 (8.54) | 5.69 (5.89) | 5.55 (6.56) |
| Days of tobacco usea (past 30 days) | 1.88 (6.02) | 0.78 (4.27) | 1.73 (6.16) |
| AUDIT | 2.95 (1.93) | 2.18 (1.60) | 2.47 (1.96) |
| Cannabis use during experimental appt. | |||
| Grams usedb | .29 (.25) | .28 (.34) | .34 (.29) |
| Time away from mobile lab | 14.47 (7.02) | 15.56 (7.39) | 17.45 (9.65) |
| Mode of ad libitum administration | |||
| Joint | 20.75% | 10.42% | 25.53% |
| Bong | 30.19% | 18.75% | 14.89% |
| Pipe | 41.51% | 60.42% | 48.94% |
| Vaporizer | 7.54% | 10.42% | 10.64% |
Note: No significant differences in demographics, cannabis use history, current cannabis use, other substance use factors, or cannabis use during the experimental appointment emerged between conditions. Standard deviations are included in parentheses.
Abbreviations: MDS, Marijuana Dependence Scale, AUDIT, Alcohol Use Disorders Identification Test.
a
Using a 30-day timeline follow-back.
b
Participants brought our scale into their home to measure the amount of study cannabis used during the experimental appointment.